Opposing function of the proprotein convertases furin and PACE4 on breast cancer cells' malignant phenotypes: Role of tissue inhibitors of metalloproteinase-1

Cancer Research

Volumn 67, Issue 19, 2007, Pages 9030-9034

  Lapierre, Marion ^a   Siegfried, Geraldine ^b   Scamuffa, Nathalie ^a   Bontemps, Yannick ^a   Calvo, Fabien ^a   Seidah, Nabil G ^c   Khatib, Abdel Majid ^a  

^a INSERM   (France)

^b Dept Environ Med Natl Inst Publ HIth   (Norway)

^c CLIN RESEARCH INSTITUTE OF MONTREAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN; FURIN; GELATINASE A; GELATINASE B; PROTEIN; PROTEIN PACE4; TISSUE INHIBITOR OF METALLOPROTEINASE 1; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CELL INVASION; CELL MIGRATION; CELL MOTILITY; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; MALIGNANT NEOPLASTIC DISEASE; PHENOTYPE; PRIORITY JOURNAL;

ALPHA 1-ANTITRYPSIN; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; COLLAGEN; FURIN; HUMANS; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; NEOPLASM INVASIVENESS; PROPROTEIN CONVERTASES; PROTEIN PRECURSORS; SERINE ENDOPEPTIDASES; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TRANSFECTION;

EID: 35148878210     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-07-0807     Document Type: Article

References (20)

1. Seidah NG, Chretien M. Proprotein and prohormone convertases: a family of subtilases generating diverse bioactive polypeptides. Brain Res 1999;848:45-62.
2. Khatib AM, Siegfried G, Chretien M, Metrakos P, Seidah NG. Proprotein convertases in tumor progression and malignancy: novel targets in cancer therapy. Am J Pathol 2002;160:1921-35.
3. Bontemps Y, Scamuffa N, Calvo F, Khatib AM. Potential opportunity in the development of new therapeutic agents based on endogenous and exogenous inhibitors of the proprotein convertases. Med Res Rev 2007;27:631-48.
4. Basak A. Inhibitors of proprotein convertases. J Mol Med 2005;83:844-55.
5. Siegfried G, Khatib AM, Benjannet S, Chretien M, Seidah NG. The proteolytic processing of pro-platelet-derived growth factor-A at RRKR(86) by members of the proprotein convertase family is functionally correlated to platelet-derived growth factor-A-induced functions and tumorigenicity. Cancer Res 2003;63:1458-63.
6. Siegfried G, Basak A, Prichett-Pejic W, et al. Regulation of the stepwise proteolytic cleavage and secretion of PDGF-B by the proprotein convertases. Oncogene 2005;24:6925-35.
7. Siegfried G, Basak A, Cromlish JA, et al. The secretory proprotein convertases furin, PC5, and PC7 activate VEGF-C to induce tumorigenesis. J Clin Invest 2003;111:1723-32.
8. Khatib AM, Siegfried G, Prat A, Luis J, Chretien M, Metrakos P, Seidah NG. Inhibition of proprotein convertases is associated with loss of growth and tumorigenicity of HT-29 human colon carcinoma cells: importance of insulin-like growth factor-1 (IGF-1) receptor processing in IGF-1-mediated functions. J Biol Chem 2001;276:30686-93.
9. Jean F, Stella K, Thomas L, et al. a1-Antitrypsin Portland, a bioengineered serpin highly selective for furin: application as an antipathogenic agent. Proc Natl Acad Sci U S A 1998;95:7293-8.
10. Cheng M, Watson PH, Paterson JA, Seidah N, Chretien M, Shiu RP. Pro-protein convertase gene expression in human breast cancer. Int J Cancer 1997;71:966-71.
11. Duffy MJ, Maguire TM, Hill A, McDermott E, O'Higgins N. Metalloproteinases: role in breast carcinogenesis, invasion and metastasis. Breast Cancer Res 2000;2:252-7.
12. Zhong M, Munzer JS, Basak A, et al. The prosegments of furin and PC7 as potent inhibitors of proprotein convertases. In vitro and ex vivo assessment of their efficacy and selectivity. J Biol Chem 1999;274:33913-20.
13. Nour N, Basak A, Chretien M, Seidah NG. Structure-function analysis of the prosegment of the proprotein convertase PC5A. J Biol Chem 2003;278:2886-95.
14. Bassi DE, Mahloogi H, Al-Saleem L, Lopez De Cicco R, Ridge JA, Klein-Szanto AJ. Elevated furin expression in aggressive human head and neck tumors and tumor cell lines. Mol Carcinog 2001;31:224-32.
15. Fu Y, Campbell EJ, Shepherd TG, Nachtigal MW. Epigenetic regulation of proprotein convertase PACE4 gene expression in human ovarian cancer cells. Mol Cancer Res 2003;1:569-76.
16. Bassi DE, Lopez De Cicco R, Mahloogi H, Zucker S, Thomas G, Klein-Szanto AJ. Furin inhibition results in absent or decreased invasiveness and tumorigenicity of human cancer cells. Proc Natl Acad Sci U S A 2001;98:10326-31.
17. Nejjari M, Berthet V, Rigot V, et al. Inhibition of proprotein convertases enhances cell migration and metastases development of human colon carcinoma cells in a rat model. Am J Pathol 2004;164:1925-33.
18. Lopez de Cicco R, Bassi DE, Zucker S, Seidah NG, Klein-Szanto AJ. Human carcinoma cell growth and invasiveness is impaired by the propeptide of the ubiquitous proprotein convertase furin. Cancer Res 2005;65:4162-71.
19. Bassi DE, Mahloogi H, Lopez De Cicco R, Klein-Szanto A. Increased furin activity enhances the malignant phenotype of human head and neck cancer cells. Am J Pathol 2003;162:439-47.
20. Mahloogi H, Bassi DE, Klein-Szanto AJ. Malignant conversion of non-tumorigenic murine skin keratinocytes overexpressing PACE4. Carcinogenesis 2002;23:565-72.